Wat is de prijs voor OmniAb, Inc. (OABI)

Het prijs van OmniAb, Inc. (OABI) is $4.48

Wat is de marktkapitalisatie voor OmniAb, Inc. (OABI)

Marktkapitalisatie voorOmniAb, Inc. (OABI) is $649.33M

OmniAb, Inc. (OABI) Winst

OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.

Jaar	Winst	Wijzigen
Niet genoeg gegevens voor de verstrekte datums.

Jaar

Winst

Wijzigen

Niet genoeg gegevens voor de verstrekte datums.

Bedrijf	Winst	Winstverschil	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
CSL Limited CSL.AX	$-4.02B	-	AU
Moderna, Inc. MRNA.US	$-3.09B	-	US
Lonza Group AG LONN.SW	-	-	CH

Bedrijf

Winst

Winstverschil

Land

Vertex Pharmaceuticals Incorporated

VRTX.US

$5.27B

Argenx SE

ARGX.US

$1.95B

CSL Limited

CSL.AX

$-4.02B

Moderna, Inc.

MRNA.US

$-3.09B

Lonza Group AG

LONN.SW

OmniAb, Inc.

OABI

Categorie